Patients with cardiac sarcoma had a median survival time of 19 months; surgery and chemotherapy significantly improved prognosis compared to no treatment.
Primary cardiac sarcoma carries a poor prognosis with a median survival of 19 months, though patients suitable for surgery and those receiving chemotherapy demonstrate more favorable outcomes.
Absolute Event Rate: 0% vs 0%
Background: Primary cardiac sarcomas are exceptionally rare malignant tumors of the heart, representing the most common type of primary cardiac malignancy.Due to their low incidence, knowledge regarding clinicopathological features and prognostic factors remains limited, and evidence-based treatment strategies are limited.The aim of this study was to determine the clinicopathological features and prognosis of patients with cardiac sarcoma.Methods: This retrospective study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with primary cardiac sarcoma between 2000 and 2022.Demographic, clinicopathological, and treatment variables were extracted from the database.Survival outcomes were estimated using Kaplan-Meier analysis, and independent prognostic factors were determined through multivariate Cox proportional hazards regression.Results: Two hundred and thirty-four patients who met the study criteria were identified and analyzed.The most common sarcoma types were NOS sarcoma (16.7%), giant cell sarcoma (16.7%), leiomyosarcoma (12%), spindle cell sarcoma (9.8%), and synovial sarcoma (9%).Patients were more frequently diagnosed as localized or locally advanced (localized: 40.5%, locally advanced: 30.3%).The most common sites of metastasis in stage 4 patients were bone (8%), lung (8%), brain (4.4%), and liver (2.9%).Cancer-related surgery was performed in 75.9% of patients, 23.1% received radiotherapy, and 42.7% received chemotherapy.The median survival time was 19 months (95% CI, 12.8-25.1).1-, 3-, and 5-year survival rates were 60.9%, 35.5%, and 21.5%, respectively.Factors affecting survival were evaluated using multivariate analysis and identified as age (p = 0.007), gender (p = 0.799), sarcoma type (p = 0.231), surgery (p = 0.002), radiotherapy (p = 0.774), chemotherapy (p = 0.010), and stage at diagnosis (p = 0.123). Conclusions:In this study, we found that patients with cardiac sarcoma had a poor prognosis at diagnosis.We identified patient age and treatment methods as important parameters affecting disease prognosis.We have demonstrated that patients who are suitable for surgery and those who receive chemotherapy have more favorable prognoses.
Doğan et al. (Sun,) reported a other. Patients with cardiac sarcoma had a median survival time of 19 months; surgery and chemotherapy significantly improved prognosis compared to no treatment.